Imam Waked
A5011520858- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis Viruses Studies and Epidemiology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Organ Transplantation Techniques and Outcomes
- Parasites and Host Interactions
- Immune Cell Function and Interaction
- Systemic Lupus Erythematosus Research
- Cancer Mechanisms and Therapy
- Gallbladder and Bile Duct Disorders
- Metabolomics and Mass Spectrometry Studies
- Influenza Virus Research Studies
- MicroRNA in disease regulation
- Alcohol Consumption and Health Effects
- Pediatric Hepatobiliary Diseases and Treatments
- Liver Diseases and Immunity
- Immune Response and Inflammation
- Diet, Metabolism, and Disease
- Monoclonal and Polyclonal Antibodies Research
- Cancer, Lipids, and Metabolism
- Renal cell carcinoma treatment
- Forensic Toxicology and Drug Analysis
Menoufia University
2016-2025
Center for Disease Analysis
2022
National Organization for Drug Control and Research
2022
Liver Institute Northwest
2014-2021
General Department of Preventive Medicine
2011
Mansoura University
2006-2008
Engineering and Physical Sciences Research Council
2008
St Mary's Hospital
2008
Imperial College London
2008
GlaxoSmithKline (United Kingdom)
2008
Summary The disease burden of hepatitis C virus ( HCV ) is expected to increase as the infected population ages. A modelling approach was used estimate total number viremic infections, diagnosed, treated and new infections in 2013. In addition, model change progression mortality 2013–2030. Finally, expert panel consensus capture current treatment practices each country. Using today's paradigm, projected decline or remain flat all countries studied. However, same time period, individuals with...
•With only 10 years left to meet the WHO's hepatitis elimination targets, COVID-19 is impacting progress.•A 1-year delay in HCV programs could cause excess morbidity and mortality.•A 72,000 deaths from HCV.•Most would be lower middle income high-income groups. Background & AimsCoronavirus disease 2019 (COVID-19) has placed a significant strain on national healthcare systems at critical moment context of elimination. Mathematical models can used evaluate possible impact programmatic delays...
Screening Program to Eliminate Hepatitis C in Egypt In 2018, the Egyptian government initiated a massive hepatitis screening and treatment program. The Ministry of Health set goal screenin...
Summary The number of hepatitis C virus ( HCV ) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used forecast two treatment scenarios: (i) the impact increased efficacy keeping treated patients constant and (ii) increasing rate. This analysis suggests that successful diagnosis a small proportion can contribute significantly reduction burden in countries studied. largest ‐related morbidity mortality occurs when combined higher...
<h3>Objective</h3> To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with pangenotypic activity, administered peginterferon-alfa-2a/ribavirin. <h3>Design</h3> In this Phase 2b double-blind, placebo-controlled study, treatment-naive adults genotype 1 (N=365) or 4 (N=30) infection were randomly assigned (2:2:1) to daclatasvir 20 mg 60 mg, placebo once daily plus weekly peginterferon-alfa-2a twice-daily ribavirin. Daclatasvir recipients achieving protocol-defined...
Treatment of chronic hepatitis C using combination sofosbuvir (SOF) and daclatasvir (DCV) was used in several clinical trials multicentre studies, which were somewhat limited to genotypes 1-3. The national program Egypt is SOF-DCV for large scale treatment.To assess the efficacy safety combined treating patients with HCV-G4 a real-world setting.Data outcome HCV who treated 12 weeks generic medications: DCV 60 mg plus SOF 400 ± ribavirin (RBV) within treatment are presented. Treatment-naïve...
The heterogeneity of intermediate-stage hepatocellular carcinoma (HCC) and the widespread use transarterial chemoembolization (TACE) outside recommended guidelines have encouraged development scoring systems that predict patient survival. aim this study was to build validate statistical models offer individualized survival prediction using response TACE as a variable.Clinically relevant baseline parameters were collected for 4,621 patients with HCC treated at 19 centers in 11 countries. In...
Chronic hepatitis C virus (HCV) infection is a major public health problem in many low- and middle-income countries. In 2015, Egypt's HCV prevalence of 7% among adults was the highest world accounted for 7.6% country's mortality. 2014, Egypt embarked on an aggressive screening treatment program that evolved into national strategy to eliminate as threat by 2021.In this qualitative case study, we analyzed control using Kingdon framework understand how problem, policy, political streams merged...
Several HCC risk stratification scores were developed; however, none has been prospectively validated. The primary aim is to validate the clinical utility of six in large prospective study F3-4 patients achieving SVR following DAAs according EASL guidelines. secondary explore whether individualized improves detection at early stages amenable curative treatment.
Hepatitis C virus (HCV) is considered the most common etiology of chronic liver disease (CLD) in Egypt, where prevalence antibodies to HCV (anti-HCV) approximately 10-fold greater than United States and Europe. Reported are results that show role both overt occult CLD, risk factors for CLD infection, relative importance HCV, hepatitis B, or causing hepatic morbidity. Case patients included 237 new outpatients at National Liver Institute. Controls comprised 212 sex- age-matched neighbors...